Pfizer

Pfizer (PFE) Stock After Hours on December 9, 2025: Obesity Pill Deal, RSV Questions, and What to Watch Before the Opening Bell

Pfizer Inc. (NYSE: PFE) finished a volatile Tuesday session on December 9, 2025 under pressure, then stabilized in after-hours trading as investors digested a big new obesity-drug licensing deal and fresh headlines around RSV therapies. With the next U.S. market

10 December 2025

Pfizer (PFE) Stock on November 30, 2025: Institutional Buying, Metsera Deal and a 6.7% Dividend Yield

Pfizer Inc. (NYSE: PFE) is back in the spotlight as of November 30, 2025. Fresh regulatory filings show new institutional buying, analysts are nudging price targets higher, and the company has closed a multibillion‑dollar obesity deal while reshaping its post‑pandemic

30 November 2025

Dividend Investing · Institutional Investors · NYSE:PFE · Pfizer · Pharmaceutical Industry · Stock Market

Pfizer Stock Surges on Trump’s Drug Price Deal & $7B Obesity Gamble – Is This the Comeback Investors Hoped For?

Technical Analysis – Levels to Watch From a technical perspective, Pfizer’s stock has been basing in the low-to-mid $20s and has yet to break out of its longer-term downtrend. The 52-week range is roughly $20.92 to $30.43 ts2.tech, and the

1 November 2025

Business News · Healthcare Investments · NYSE:PFE · Pfizer · Pharma Industry · Stock Market

Pfizer News 1 November 2025 - 10 December 2025

Pfizer (PFE) Stock After Hours on December 9, 2025: Obesity Pill Deal, RSV Questions, and What to Watch Before the Opening Bell

Pfizer (PFE) Stock on November 30, 2025: Institutional Buying, Metsera Deal and a 6.7% Dividend Yield

Pfizer Stock Surges on Trump’s Drug Price Deal & $7B Obesity Gamble – Is This the Comeback Investors Hoped For?